Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth Devine

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Plos One|April 28, 2022
Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell diseaseKate M Johnson, Boshen Jiao, M A Bender, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2022
Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic ReviewBoshen Jiao, Anirban Basu, Scott Ramsey, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 1, 2022
A landscape analysis and discussion of value of gene therapies for sickle cell diseaseDalyna Quach, Boshen Jiao, Anirban Basu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 1, 2022
Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice ExperimentEnrique M Saldarriaga, Brett Hauber, Josh J Carlson, et al.
Blood Advances|May 16, 2022
Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insuranceKate M Johnson, Boshen Jiao, Scott D Ramsey, et al.
Blood Advances|March 17, 2023
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiariesBoshen Jiao, Kate M Johnson, Scott D Ramsey, et al.
Open Forum Infectious Diseases|September 6, 2018
The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative InfectionsSarah Baradaran, Douglas J Black, Katelyn R Keyloun, et al.
International Journal of Medical Informatics|December 9, 2015
Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alertsAdam A Nishimura, Brian H Shirts, Joseph Salama, et al.
Experimental Hematology & Oncology|December 10, 2013
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparisonJames Signorovitch, Elyse Swallow, Evan Kantor, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 12, 2019
Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary InterventionM Ragan Hart, Louis P Garrison, Debra L Doyle, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Plos One|April 28, 2022
Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell diseaseKate M Johnson, Boshen Jiao, M A Bender, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2022
Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic ReviewBoshen Jiao, Anirban Basu, Scott Ramsey, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|April 1, 2022
A landscape analysis and discussion of value of gene therapies for sickle cell diseaseDalyna Quach, Boshen Jiao, Anirban Basu, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 1, 2022
Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice ExperimentEnrique M Saldarriaga, Brett Hauber, Josh J Carlson, et al.
Blood Advances|May 16, 2022
Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insuranceKate M Johnson, Boshen Jiao, Scott D Ramsey, et al.
Blood Advances|March 17, 2023
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiariesBoshen Jiao, Kate M Johnson, Scott D Ramsey, et al.
Open Forum Infectious Diseases|September 6, 2018
The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative InfectionsSarah Baradaran, Douglas J Black, Katelyn R Keyloun, et al.
International Journal of Medical Informatics|December 9, 2015
Physician perspectives of CYP2C19 and clopidogrel drug-gene interaction active clinical decision support alertsAdam A Nishimura, Brian H Shirts, Joseph Salama, et al.
Experimental Hematology & Oncology|December 10, 2013
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparisonJames Signorovitch, Elyse Swallow, Evan Kantor, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 12, 2019
Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary InterventionM Ragan Hart, Louis P Garrison, Debra L Doyle, et al.
Pageof 15